WARNING! More information in the Privacy Policy and the use of cookies Press releases Warsaw, June 22, 2016 Ezetrol Bioton is expanding cooperation with MSD BIOTON SA concluded an agreement with MSD, part of the American concern Merck & Co., under which it will cooperate with MSD in the development of the hypercholesterolemia treatment market with the innovative drug Ezetrol (ezetimibe). read more Warsaw, May 27, 2016 CHANGES IN BIOTON CORPORATE BODIES On May 25, 2016, the Supervisory Board of Bioton SA (" Bioton ", "the Company ") decided to appoint a strategy development committee whose main task is to introduce Bioton's operations to the global level and to develop the portfolio of diabetes products as the main area of the Company's operations. In connection with the above, the Supervisory Board decided to delegate its Chairman, Mr. Jubo Liu and Vice-Chairman, Mr. Dariusz Trzeciak, to exercise direct supervision over the development process and implementation of the new strategy of the Company. read more Current reports Warsaw, September 30, 2016 Current report (RB 2016/45) of September 30, 2016, at 18.49 UTC Postponement of the closing date of the transaction read more Warsaw, August 30, 2016 Current report (RB 2016/44) of August 30, 2016, at 19.02 UTC Conclusion of an agreement for the sale of shares in MJ BIOTON Life Sciences Ltd read more About company Mission of the company Authorities of BIOTON SA History of BIOTON SA Research and development Quality management Sales targets and global expansion Companies of the BIOTON SA Group Cooperation with the European Union Press office Privacy policy and the use of cookies contact AVAILABILITY OF GENSUPEN Press office Contact for media: Renata Ożarowska ozarowskar@bioton.pl Tel .: +22 721 40 02 Contact for investors: Renata Ożarowska ozarowskar@bioton.pl Tel .: +22 721 40 02 © 2016 BIOTON SA phone: +48 22 721 40 00 fax: +48 22 721 13 33 bioinfo@bioton.pl